Economic methods for measuring the quality of life associated with HIV infection

Quality of Life Research

Volumn 8, Issue 6, 1999, Pages 471-480

  Bayoumi, Ahmed M ^a   Redelmeier, Donald A ^b  

^a ST MICHAEL'S HOSPITAL   (Canada)

^b NONE

Author keywords

Economic value of life; HIV infections; Quality of life

Indexed keywords

CD4 ANTIGEN;

ARTICLE; COST EFFECTIVENESS ANALYSIS; ECONOMIC ASPECT; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; QUALITY OF LIFE; RATING SCALE; SCORING SYSTEM; TREATMENT OUTCOME;

ADULT; FEMALE; HEALTH STATUS; HIV INFECTIONS; HUMANS; MALE; MIDDLE AGED; QUALITY OF LIFE; VALUE OF LIFE;

EID: 0032885818     PISSN: 09629343     EISSN: None     Source Type: Journal    
DOI: 10.1023/A:1008969512182     Document Type: Article

References (47)

1. Gold MR, Seigel JF, Russell LB, Weinstein MC (eds). Cost-effectiveness in health and medicine. New York: Oxford University Press, 1996.
2. Detsky AS, Naglic IG. A clinician's guide to cost-effectiveness analysis. Ann Int Med 1990; 113: 147-154.
3. Rose DN, Sacks HS. Cost-effectiveness of cytomegalovirus (CMV) disease prevention in patients with AIDS: oral ganciclovir and CMV polymerase chain reaction testing. AIDS 1997; 11: 883-887.
4. Gulick RM. Current antiretroviral therapy: an overview. Qual Life Res 1997; 6: 471-474.
5. Wu AW, Lamping DL. Assessment of quality of life in HIV disease. AIDS 1994; 8: S349-S359.
6. Shumaker SA, Ellis S, Naughton M. Assessing health-related quality of life in HIV disease: key measurement issues. Qual Life Res 1997; 6: 475-480.
7. Tsevat J, Dawson NV, Matchar DB. Assessing quality of life and preferences in the seriously ill using utility theory. J Clin Epidemiol 1990; 43(Suppl): 73S-77S.
8. Torrance GW. Utility approach to measuring health-related quality of life. J Chron Dis 1987; 6: 593-600.
9. Torrance GW, Feeny D. Utilities and quality-adjusted life years. Int J Tech Assess Health Care 1989; 5: 559-575.
10. Froberg DG, Kane RL. Methodology for measuring health-state preferences I: measurement strategies. J Clin Epidemiol 1989; 42: 345-354.
11. Froberg DG, Kane RL. Methodology for measuring health-state preferences II: scaling methods. J Clin Epidemiol 1989; 42:459-471.
12. Nord E. Methods for quality adjustment of life years. Soc Sci Med 1992; 34: 559-569.
13. Lamping DL. Methods for measuring outcomes to evaluate interventions to improve health-related quality of life in HIV infection. Psychology and Health. 1994; 9: 31-49.
14. Copfer AE, Ampel NM, Hughes TE, et al. The use of two measures of health-related quality of life in HIV-infected individuals: a cross-sectional comparison. Qual Life Res 1996; 5: 281-286.
15. Tsevat J, Solzan JG, Kuntz KM, Ragland J, Currier JC, Sell RL, Weinstein MC. Health values of patients infected with Human Immunodeficiency Virus: relationship to mental health and physical functioning. Med Care 1996; 34: 44-57.
16. Revicki DA, Wu AW, Murray MI. Change in clinical status, health status, and health utility outcomes in HIV-infected patients. Med Care 1995; 33(Suppl): AS173-AS182.
17. Owens DK, Cardinalli AB, Nease RF. Physicians' assessments of the utility of health states associated with Human Immunodeficiency Virus (HIV) and Hepatitis B Virus (HBV) infection. Qual Life Res 1997; 6: 77-86.
18. Holtgrave DR, Pinkerton SD. Updates of cost of illness and quality of life estimates for use in economic evaluations of HIV prevention programs. J Acquir Immune Defic Syndr Hum Retrovirol 1997; 16: 54-62.
19. Bult JR, Hunink MGM, Tsevat J, Weinstein MC. Heterogeneity in the relationship between the Time Tradeoff and Short Form-36 for HIV-infected and primary care patients. Med Care 1998; 36: 523-532.
20. Torrance GW. Measurement of health state utilities for economic appraisal: a review. J Health Econ 1986; 5: 1-30.
21. Wu AW, Revicki DA, Jacobson D, Malitz FE. Evidence for reliability, validity and usefulness of the Medical Outcomes Study HIV health survey (MOS-HIV). Qual Life Res 1997; 6: 481-493.
22. Mocroft AJ, Johnson MA, Sabin CA, et al. Staging system for clinical AIDS patients. Lancet 1995; 346: 12-27.
23. Turner BJ, Markson LE, McKee L, Houchens R, Fanning T. The AIDS-defining diagnosis and subsequent complications: a survival-based severity index. J Acquir Immune Defic Syndr 1991; 4: 1059-1071.
24. Redelmeier DA, Detsky AS. A clinician's guide to utility analysis. Primary Care: Clinics in Office Practice 1995; 14: 82-90.
25. Bayoumi AM, Redelmeier DA. Preventing Mycobacterium avium complex in patients who are using protease inhibitors: a cost-effectiveness analysis. AIDS 1998; 12: 1503-1512.
26. Torrance GW. Social preferences for health states: an empirical evaluation of three measurement techniques. Socio-Econ Planning Sci 1976; 10: 129-136.
27. Tversky A, Kahneman D. The framing of decisions and the psychology of choice. Science 1981; 211: 453-458.
28. Froberg DG, Kane RL. Methodology for measuring health-state preferences - III: population and context effects. J Clin Epidemiol 1989; 42: 585-592.
29. Hershey JC, Kunreuther HC, Schoemaker PJH. Sources of bias in assessment procedures for utility functions. Management Sci 1982, 28: 936-955.
30. McNeil BJ, Pauker SG, Sox HC, Tversky A. On the elicitation of preferences for alternative therapies. N Engl J Med 1982; 306: 1259-1262.
31. Gerard K, Dobson M, Hall J. Framing and labelling effects in health descriptions: quality adjusted life years for treatment of breast cancer. J Clin Epidemiol 1993; 46: 77-84.
32. Torrance GW, Furlong W, Feeny D, Boyle M. Multiattribute preference functions: Health utilities index. PharmacoEconomics 1995; 7: 503-520.
33. Fecny D, Furlong W, Boyle M, Torrance GW. Multi-attribute health status classification systems: health utilities index. PharmacoEconomics 1995; 7: 490-502.
34. Wu AW, Rubin HR, Mathews WC, et al. A health status questionnaire using 30 items from the Medial Outcomes Study: preliminary validation in persons with early HIV infection. Med Care 1991; 29: 786-798.
35. Torrance GW, Feeny DH, Furlong WJ, Barr RD, Zhang Y, Wang Q. Multiattribute utility function for a comprehensive health status classification system. Health Utilities Index Mark 2. Med Care 1996; 34: 702-722.
36. Wu AW, Mathews WC, Brysk LT, et al. Quality of life in a placebo-controlled trial of zidovudine in patients with AIDS and AIDS-related complex. J Acquir Immune Defic Syndr 1990; 3: 683-690.
37. Fleiss JL. Statistical methods for rates and proportions. 2nd ed. New York: Wiley, 1981.
38. Gold MR, Patrick DL, Torrance GW, et al. Identifying and valuing health outcomes. In: Gold MR, Seigel JE, Russell LB, Weinstein MC (eds). Cost-effectiveness in health and medicine. New York: Oxford University Press, 1996: 82-134.
39. Cunningham WE. Bozzette SA, Hays RD, Kanouse DE, Shapiro MF. Comparison of health-related quality of life in clinical trial and nonclincal trial human-immunodeficiency virus-infected cohorts. Med Care 1995; 33: AS15-AS25.
40. Llewellyn-Thomas H, Sutherland HJ, Tibshirani R, Ciampi A, Till JE, Boyd NF. Describing health states: methodologic issues in obtaining values For health states. Med Care 1984; 22: 542-552.
41. Read JL, Quinn RJ, Berwick DM, Fineberg HV, Weínstein MC. Preferences for health outcomes: Comparison of assessment methods. Med Decis Making 1991; 14: 82-90.
42. Dolan P, Gudex C, Kind P, Williams A. Valuing health states: a comparison of methods. J Health Econ 1996; 15: 209-231.
43. Stiggelbout AM, Kiebert GM, Kievitt J, Leer JWH, Stoter G, DeHacs JCJM. Utility assessment in cancer patients: adjustment of time tradeoff scores for the utility of life years and comparison with standard gamble scores. Med Decis Making 1994; 14: 82-90.
44. Hornberger JC, Redelmeier DA, Petersen J. Variability among methods to assess patients' well-being and consequent effect on a cost-effectiveness analysis. J Clin Epidemiol 1992; 45: 505-512.
45. Bombardier C, Wolfson AD, Sinclair AJ, McGeer A. Comparison of three preference measurement methodologies in the evaluation of a function status index. In: Deber RB, Thompson CG (eds). Choices in health care: decision-making and evaluation of effectiveness. Toronto: 1982: 145-159.
46. Fowler FJ, Cleary PD, Massagli MP, Weissman J, Epstein A. The role of reluctance to give up life in the measurement of values of health states. Med Decis Making 1995; 15: 95-200.
47. Owens DK, Nease RF. Occupational exposure to human immunodeficiency virus and hepatitis B virus: a comparative analysis of risk. Am J Med 1992; 92: 503-512.